Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of ginkgo leaf tablets combined with compound carbidopa on patients with Parkinson's disease

Yan Huang^1,2, Bo Du², Shiguang Zhu², Yingfeng Mu², Deqin Geng^1,2

¹Nanjing Medical University, Nanjing, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; ²Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

For correspondence:- Deqin Geng Email: gengdeqin@126.com Tel:+8618052268197

Accepted: 21 July 2023 Published: 31 August 2023

Citation: Huang Y, Du B, Zhu S, Mu Y, Geng D. Effect of ginkgo leaf tablets combined with compound carbidopa on patients with Parkinson's disease. Trop J Pharm Res 2023; 22(8):1675-1681 doi: 10.4314/tjpr.v22i7.19

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the effect of a combination of ginkgo leaf tablets with compound carbidopa tablets on cognitive function, serum homocysteine (Hcy), malondialdehyde (MDA) and neuron-specific enolase (NSE) levels in patients with Parkinson's disease (PD).

Methods: A total of eighty (80) PD patients admitted to The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China between December 2020 and December 2022 were randomly divided into two groups: Western medicine group (n = 40, using compound carbidopa tablets alone) and combination group (n = 40, using ginkgo leaf tablets combined with compound carbidopa tablets), and orally treated for 3 months. Mini-mental state examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to assess cognitive function before and after treatment. High-performance liquid chromatography was used to determine serum Hcy levels, while enzyme-linked immunosorbent assay (ELISA) was used to evaluate serum MDA and NSE levels. Adverse reactions were also recorded during treatment.

Results: Total response rate following treatment in combination group was significantly higher than in Western medicine group (95.00 vs 80.00 %, p < 0.05). After treatment, MMSE and MoCA scores in combination group were significantly higher (p < 0.05) than those in Western medicine group, while serum Hcy, MDA and NSE levels in combination group were significantly lower than those in Western medicine group (p < 0.05). During treatment, there was no significant difference in incidence of adverse reactions between the two groups (p > 0.05).

Conclusion: Ginkgo leaf tablets in combination with carbidopa significantly improve cognitive functions associated with PD with high safety, when compared to carbidopa tablets alone. However, further clinical trials are commended to validate these findings.

Keywords: Ginkgo leaf tablets, Carbidopa tablet, Parkinson’s disease, Cognitive function, Homocysteine, Malondialdehyde, Neuron-specific enolase